233 related articles for article (PubMed ID: 23896476)
21. EVG/COBI/FTC/TAF Bioequivalence Comparing Whole Tablets with Tablets Dissolved in Tap Water.
Andrade A; Fuchs EJ; Marzinke MA; Abdul Massih S; Breakey J; Beselman S; McNicholl I; Hendrix CW
AIDS Res Hum Retroviruses; 2023 Jan; 39(1):38-43. PubMed ID: 36301928
[TBL] [Abstract][Full Text] [Related]
22. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
[TBL] [Abstract][Full Text] [Related]
23. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Squillace N; Bozzi G; Colella E; Gori A; Bandera A
Drug Des Devel Ther; 2018; 12():3635-3643. PubMed ID: 30464395
[TBL] [Abstract][Full Text] [Related]
24. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL
HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960
[TBL] [Abstract][Full Text] [Related]
25. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Zolopa A; Sax PE; DeJesus E; Mills A; Cohen C; Wohl D; Gallant JE; Liu HC; Plummer A; White KL; Cheng AK; Rhee MS; Szwarcberg J;
J Acquir Immune Defic Syndr; 2013 May; 63(1):96-100. PubMed ID: 23392460
[TBL] [Abstract][Full Text] [Related]
26. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.
El-Sheikh AA; Greupink R; Wortelboer HM; van den Heuvel JJ; Schreurs M; Koenderink JB; Masereeuw R; Russel FG
Transl Res; 2013 Dec; 162(6):398-409. PubMed ID: 24036158
[TBL] [Abstract][Full Text] [Related]
27. A role for the organic anion transporter OAT3 in renal creatinine secretion in mice.
Vallon V; Eraly SA; Rao SR; Gerasimova M; Rose M; Nagle M; Anzai N; Smith T; Sharma K; Nigam SK; Rieg T
Am J Physiol Renal Physiol; 2012 May; 302(10):F1293-9. PubMed ID: 22338083
[TBL] [Abstract][Full Text] [Related]
28. Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.
Yamada H; Ikushima I; Nemoto T; Ishikawa T; Ninomiya N; Irie S
Clin Pharmacol Drug Dev; 2018 Feb; 7(2):132-142. PubMed ID: 28581645
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
German P; Warren D; West S; Hui J; Kearney BP
J Acquir Immune Defic Syndr; 2010 Nov; 55(3):323-9. PubMed ID: 20683270
[TBL] [Abstract][Full Text] [Related]
30. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.
Bousquet L; Pruvost A; Guyot AC; Farinotti R; Mabondzo A
Antimicrob Agents Chemother; 2009 Mar; 53(3):896-902. PubMed ID: 19075072
[TBL] [Abstract][Full Text] [Related]
31. Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment.
Manzardo C; Gatell JM
AIDS Rev; 2014; 16(1):35-42. PubMed ID: 24584107
[TBL] [Abstract][Full Text] [Related]
32. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.
Feng JY; Ly JK; Myrick F; Goodman D; White KL; Svarovskaia ES; Borroto-Esoda K; Miller MD
Retrovirology; 2009 May; 6():44. PubMed ID: 19439089
[TBL] [Abstract][Full Text] [Related]
33. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
34. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
[TBL] [Abstract][Full Text] [Related]
35. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
36. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management.
Gutiérrez F; Fulladosa X; Barril G; Domingo P
AIDS Rev; 2014; 16(4):199-212. PubMed ID: 25350530
[TBL] [Abstract][Full Text] [Related]
37. Probenecid-Boosted Tenofovir: A Physiologically-Based Pharmacokinetic Model-Informed Strategy for On-Demand HIV Preexposure Prophylaxis.
Liu SN; Desta Z; Gufford BT
CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):40-47. PubMed ID: 31749296
[TBL] [Abstract][Full Text] [Related]
38. Renal Drug Transporters and Drug Interactions.
Ivanyuk A; Livio F; Biollaz J; Buclin T
Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
[TBL] [Abstract][Full Text] [Related]
39. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
[TBL] [Abstract][Full Text] [Related]
40. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
Kiser JJ; Aquilante CL; Anderson PL; King TM; Carten ML; Fletcher CV
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):298-303. PubMed ID: 18398970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
